Effects of angiopeptin on transplant arteriosclerosis in the rat

Abstract The influence of the somatostatin analogue angiopeptin on transplant arteriosclerosis was investigated using two aortic transplantation rat models. One was characterized by ischemia/reperfusion-induced changes in syngeneic transplants while immunologically induced changes dominated in the other allogeneic model. Angiopeptin, 100 μg/kg per day, was administered continuously until the sacrifice of the rats after 8 weeks. No additional immunosuppression was used in either model. An image analysis system was used to quantify the intimal and medial thicknesses of the grafts. In the syngeneic grafts, the intimal thickness was less than 50% of that of control grafts (P < 0.05), but no difference was seen in the allogeneic model. The expression of selected cells, TGF-βs, and PDGF and PDGF α-receptors was detected immunohistochemically and displayed a similar picture in control and angiopeptin-treated grafts in both models. We conclude that angiopeptin has no clear immunosuppressive properties but may counteract ischemia-induced transplant arteriosclerosis.

Key words Arteriosclerosis, angiopeptin, rat · Angiopeptin, arteriosclerosis, rat · Aorta transplantation, arteriosclerosis.

Introduction

Chronic vascular rejection (CVR) is characterized by excessive intimal thickening of the vessel wall and is a major cause of diminished long-term survival of transplanted organs [25]. Because of the prominent vascular changes, CVR is often called transplant arteriosclerosis. The factors responsible for the initiation and progression of CVR are not completely understood. However, CVR can be induced and influenced by an immunological response to incompatible antigens [20], by ischemia/reperfusion injury [5, 38, 40], and by infections such as cytomegalovirus [16].

Several therapeutic substances, including peptides, have been used in attempts to inhibit or modify transplant arteriosclerosis. One of these synthetic peptides is angiopeptin. It is a stable and long-acting octapeptide, an analogue to somatostatin, with the amino acid sequence: D-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH₂. It has been shown that angiopeptin has an inhibitory effect on the proliferation of smooth muscle cells (SMCs) in rat carotid artery explants [36] and that it also inhibits DNA synthesis in SMCs after balloon angioplasty of the aorta in rabbits [2]. The postulated inhibitory effects of angiopeptin on immune cells are poorly investigated in contrast to the related peptide somatostatin. It is clear that somatostatin inhibits the proliferation of...
lymphocytes and their natural killer activity [1, 26]. It also inhibits the growth of malignant cells in both established cell lines [27, 34] and primary cultures [4, 24, 35]. Binding sites for somatostatin have been demonstrated in both lymphocytes and monocytes [3, 31]. Definite information on the immunomodulatory effect of angiopeptin is not available [13]. In accelerated transplant arteriosclerosis, it is clear that angiopeptin has an inhibitory effect on myointimal proliferation [13], but the mechanisms is only partially known. In the development of CVR and spontaneous arteriosclerosis, several growth factors and their receptors, e.g., platelet-derived growth factor (PDGF) and its receptors, may play an important role [9, 28]. It is known that macrophages can produce PDGF and, thus, stimulate the proliferation of intimal cells [29]. Furthermore, the expression of PDGF receptors may be modified or upregulated by a variety of factors, e.g., transforming growth factor-β (TGF-β) and oxidized low-density lipoprotein cholesterol [33]. This suggests an attractive hypothesis, namely, that the inhibitory effect of angiopeptin on myointimal proliferation is caused by the synthesis of growth factors [7] and cytokines secreted by activated lymphocytes and monocytes. Since TGF-β inhibits proliferation of mesenchymal as well as immune cells and stimulates angiogenesis and the production of matrix proteins [30], it may be of particular interest in a pathogenetic mechanism of transplant arteriosclerosis.

CVR is considered to be caused by both immunological and nonimmunological factors [25]. In the present study, two models were used to induce morphological changes similar to CVR. In a syngeneic graft model, CVR-like changes were induced by ischemia/reperfusion injury, whereas in an allogeneic model, CVR-like changes were induced by a combination of immunological mechanisms and ischemia/reperfusion damage. Hence, it was possible to separate the influence of immunological factors from that of nonimmunological factors. The purpose of this study was to analyze and characterize the effects of angiopeptin on aortic transplant grafts with regard to the intimal and medial changes, infiltration of inflammatory and noninflammatory cells, and the production of TGF-β/s and PDGF.

Materials and methods

Animals

Male PVG (RT1<sup>a</sup>) and DA (RT1<sup>b</sup>) rats (Møllegaard, Skensved, Denmark) aged 3–4 months and weighing 120–200 g were used. The rats were negative by serological tests for the most common viruses such as Hantaan, Killian, reo 3, corona-virus, Sendai, and Theiler viruses, and for mycoplasma pneumoniae. The allogeneic transplantation were performed from DA donors to PVG recipients, and the syngeneic transplantation from PVG-to-PVG rats. Two weeks prior to surgery, the rats were allowed to get settled and received food and water ad libitum. One week before transplantation they were fed a 0.5% cholesterol pellet diet (Analy-Cen, Lidköping, Sweden).

Transplantation of aorta

Recipient rats were anesthetized with an intraperitoneal injection of a mixture of chloral hydrate, 195.5 mg/kg, and pentobarbital, 44.6 mg/kg of body weight (Eqvittin, Apoteksbolaget, Umeå, Sweden) and donor rats with thiobarbital, 120 mg/kg body weight (Inactin, Byk Gulden, Konstanz, Germany). The abdominal aorta of each recipient rat was freed just below the renal arteries to the bifurcation of the abdominal aorta. Clamps were then placed on the abdominal aorta at these sites before excising a 10 to 15-mm-long portion for transplantation from each donor rat, as described previously [20]. Portions of allogeneic grafts were stored at 4°C for 1 h in a histidine-buffered preservation solution (Frodin solution) [14] and those of syngeneic grafts for 4 h. Each graft was immediately implanted orthotopically and was anastomosed from the renal arteries to the caudal abdominal aorta using a 9–0 nylon suture (S & T Neuhausen am Rheinfall, Switzerland). The aortic clamps were then removed and patency of the new vascular connection was confirmed. After 8 weeks, the rats were anesthetized and the grafts excised. From each recipient rat, 10 to 15-mm-long nontransplanted portions of the thoracic and the abdominal aorta were harvested to serve as negative controls for image analysis and immunohistochemical stains. Each transplanted and nontransplanted portion was divided into two parts, one of which was frozen in a mixture of cold isopentane and dry ice and stored at −70°C until processed for immunohistochemistry. The other part was fixed in 4% buffered formaldehyde at room temperature and embedded in paraffin. These sections were then stained with van Gieson and Mayer’s hematoxylin and eosin for histological and comparative studies.

Treatment procedure

Angiopeptin is a nontoxic peptide that can be administered either as a subcutaneous or as an intravenous infusion. It is absorbed quickly into the bloodstream, reaching a peak plasma concentration within 10–15 min after administration [6]. After transplantation of the grafts, immediate treatment with angiopeptin is essential since SMC migration and proliferation occurs within 8 h of vascular injury [11]. For these reasons, infusion of angiopeptin, 100 µg/kg per day, (Henri Beaufour Institute, Washington, D.C., USA), was administered continuously to recipient rats by mini-osmotic pumps (Alzet-model2ML4, Aiza Corporation, Palo Alto, Calif., USA) located subcutaneously in the dorsal region (administration 1). In addition, 8 of each 16 allogeneic and 16 syngeneic grafts were immersed in angiopeptin (50 µg/ml) in the preservation solution before transplantation. Thereafter, rats received angiopeptin treatment by mini-osmotic pumps, as described above (administration 2). The pumps were replaced under anesthesia after 4 weeks.

Image analysis

Paraffin-embedded midgraft sections stained with van Gieson and Mayer’s hematoxylin and eosin were used. Image analysis was performed blindly. The areas of the lumen, intima, and media were quantified using the IMTEC image analysis system (Image Technology, Uppsala, Sweden). The sections were analyzed at a magnification ×40 using a conventional microscope. The image of the aorta was transferred to a screen and the vessel examined was cir-
The areas that the vessels occupied were quantified as follows: (i) lumen alone, (ii) lumen + intima, and (iii) lumen + intima + media. From these measurements, the thickness of the intima and media was quantified. The intima quotient \( Q_{\text{int}} = \frac{\text{Intima}}{\text{Lumen} + \text{Intima}} \times 100 \) and media quotient \( Q_{\text{med}} = \frac{\text{Media}}{\text{Lumen} + \text{Intima} + \text{Media}} \times 100 \) were calculated from the image analysis data. \( Q_{\text{int}} \) indicates the relative thickness \( \% \) of intima \( \left[ Q_{\text{int}} = \text{Intima}/(\text{Lumen} + \text{Intima}) \times 100 \right] \), and \( Q_{\text{med}} \) indicates the relative thickness \( \% \) of media \( \left[ Q_{\text{med}} = \text{Media}/(\text{Lumen} + \text{Intima} + \text{Media}) \times 100 \right] \) (Fig. 1). Therefore, a \( Q_{\text{int}} \) value of 0.0\% indicates no intimal thickening and a \( Q_{\text{med}} \) value of 100.0\% indicates a total occlusion of the lumen by thickened intima.

Immunohistochemical analysis

**Antibodies**

The following monoclonal antibodies (concentration in parentheses) were used: ED2 (1:1600) recognizing macrophages, ED1 (1:3200) recognizing monocytes, macrophages and dendritic cells (Serotec Lab. Oxford, UK), W3/25 (1:300) directed against CD4\(^+\) T lymphocytes [39], Ox8 (1:1000) directed against CD8\(^+\) T lymphocytes [39], Ox6 (1:2000) detecting major histocompatibility (MHC) class II antigen [19], antihuman coagulation factor VII (1:12000), a marker of endothelial cells (Immunsystem, Uppsala, Sweden), and anti-\(\alpha\) smooth muscle actin (1:1400) labelling \(\alpha\)-actin containing SMCs (Dakopatts Lab. Copenhagen, Denmark).

Antibodies detecting synthetic peptides corresponding to the C-terminal regions of latency-associated peptides (LAP) of two human TGF-\(\beta\) isoforms, TGF-\(\beta_1\) and \(\beta_3\) precursors were used [37]. Antibodies Ab 96 (1:10) and Ab 95 (1:10) detect anti-\(\beta_1\)-LAP and anti-\(\beta_3\)-LAP. Anti-\(\beta_1\)-LAP is directed against amino acids 262–272 of \(\beta_1\)-LAP and anti-\(\beta_3\)-LAP against amino acids 282–298 of \(\beta_3\)-LAP. Antibody Ab 99 (1:1200) was raised against latent TGF-\(\beta\)-binding protein (LTBP), which was purified from human platelets [23]. Two antibodies, PGF-007 (1:1000; Mochida, Tokyo, Japan) and PDGF-7 (1:50) [8], were used to detect PDGF and its \(\alpha\) receptors. The monoclonal antibody PGF-007 is generated against a 25 amino acid peptide derived from a region near the COOH terminus of the PDGF-B chain. The antibody recognized PDGF-AB and -BB but not PDGF-AA in immunoprecipitation experiments [32]. In acetone-fixed cells transfected with PDGF-A or -B chains, the antibody PGF-007 recognizes PDGF-AA and -BB. The antibody designated PDGF-7 was produced against a synthetic peptide of amino acids 1060–1084 of the C-terminal region of human PDGF \(\alpha\) receptor and binds to PDGF \(\alpha\)- but not to the \(\beta\)- receptor. The antibody can be used to detect the corresponding protein in both species since the C-terminal region has 100% amino acid homology in humans and rats [8]. Antibody E11 (1:100), directed against the calcium-binding receptor of human parathyroid cells, was used as an irrelevant control [15].

**Immunohistochemical procedure**

Five-micron cryostat sections of the midgraft were fixed in 100% cold acetone rinsed in 0.1 M phosphate-buffered saline solution (PBS) and immunohistochemically stained as follows. Sections of the grafts were incubated at +4°C overnight with the primary antibody diluted in PBS containing 0.1% bovine serum albumin (BSA). Biotinylated anti-mouse IgG (1:80; Vector Lab, Burlingame, Calif., USA) in PBS containing 0.1% BSA, 2% rat serum, and 2% horse serum was subsequently applied. The biotin avidin amplification system was used as recommended by the manufacturer. The sections were counterstained with Mayer's hematoxylin, mounted, and examined for antigen expressions.

**Evaluation of immunohistochemistry**

The staining intensity of the intima and media was scored on a scale ranging from 0, indicating no expression, to 3, indicating the most intense expression of antigens. Scoring was done independently by two investigators. In the event of disagreement, the sections were re-examined and a common view obtained. The final semiquantitative evaluation is presented as an average \(\pm\) standard error of the mean (SEM) of immunohistochem-

**Statistical analysis**

The allogeneic and syngeneic control and angiopeptin-treated transplants were compared using the nonparametric Mann-Whitney U-test. Its primary use is to compare irregularly distributed and independent data. The unpaired t-test was used to compare the thickness of the media in allogeneic and syngeneic control groups and in the corresponding nontransplanted portions of the abdominal aorta of recipient rats. The Mann-Whitney U-test was also used to compare the semiquantitative immunohistochemical stainings of control versus angiopeptin-treated syngeneic and allogeneic grafts.

**Results**

Six angiopeptin-treated rats and two control rats died due to surgical complications.
Morphometric measurements

The median values and ranges of the intimal and medial thickness of the syngeneic and allogeneic control and angiopeptin-treated grafts are shown in Table 1. Both administration 1 and 2 of angiopeptin in the allogeneic and syngeneic combinations were considered and presented as one group since they have a similar effect on the intimal and medial thickness.

The thickness of the intima in the allogeneic control grafts was significantly greater than in the syngeneic control grafts (P < 0.001). The medial thickness in the allogeneic control grafts was significantly less than in the syngeneic control grafts (P < 0.001). The intima was not thickened in nontransplanted portions of the abdominal and thoracic aorta in the syngeneic and allogeneic recipient rats.

**Allogeneic grafts**

Q_{int} was 32.0 % in control grafts (n = 15) and 40.0 % in angiopeptin-treated grafts (n = 16). They did not differ statistically (P = 0.36). In administration 1 and 2 of angiopeptin, Q_{int} was 38.1 % and 41.5 %, respectively (P = 0.76).

Q_{med} was 22.0 % in control allogeneic grafts (n = 15), while Q_{med} in the nontransplanted abdominal aortic portions (n = 6) was 46.3 % (P = 0.001). The Q_{med} value was 24.0 % in angiopeptin-treated grafts. The thickness of the media were similar in control and angiopeptin-treated grafts (P = 0.22). In administration 1 and 2 of angiopeptin, Q_{med} was 23.8 % and 26.1 %, respectively (P = 0.62).

**Syngeneic grafts**

The thickness of the intima was less in the syngeneic grafts of rats treated with angiopeptin (n = 16) with a Q_{int} of 5.3 % compared with control grafts (n = 10) with a Q_{int} of 20.0 % (Fig. 2). In the treated syngeneic grafts, the thickness of the intima was reduced by over 50 % (P < 0.05). Q_{int} in administration 1 and 2 of angiopeptin was 5.1 % and 6.5 %, respectively. They did not differ statistically (P = 0.76). Thickening of the intima did not occur at all in 5 of the 16 treated syngeneic grafts nor in 1 of the 9 control syngeneic grafts.

The Q_{med} values were 36.0 % and 43 %, respectively, in the syngeneic control grafts (n = 10) and nontransplanted portions of abdominal aorta of recipient rats (n = 14). Statistically, the values were similar (P = 0.36). The Q_{med} value was 41.3 % after angiopeptin treatment. The thickness of the media of these grafts was not different from that of control grafts (P = 0.41). In administration 1 and 2 of angiopeptin, Q_{med} was 44.0 % and 38.9 %, respectively (P = 0.62).

**Immunohistochemical observations**

The results of the immunohistochemical investigations of the intima and media in control and angiopeptin-treated grafts are shown in Table 2. The values of the semiquantitative evaluations of all immunohistochemical stainings were statistically similar in control versus angiopeptin-treated allogeneic and syngeneic grafts.

**Allogeneic grafts**

The entire aortic wall of control and angiopeptin-treated allogeneic grafts was infiltrated by macrophages and monocytes and fewer numbers of CD4+ and CD8+ T lymphocytes. The expression of MHC class II antigen, in control and allogeneic grafts treated with angiopeptin, was pronounced in the adventitia (data not shown), less in the media, and least in the intima. The intima in control and angiopeptin-treated grafts contained many α-actin-positive SMCs. The media of treated and control grafts consisted mainly of α-actin containing SMCs.
of MHC class II antigen was not detected in the media of angiopeptin-treated syngeneic grafts; however, some expression was seen in the intima and adventitia. Most SMCs in control and angiopeptin-treated grafts were seen in the media, but a few were also present within the intima. Few macrophages, monocytes, and CD4+ and CD8+ T lymphocytes existed in the media of control and treated grafts, and in some cases they were absent. Interruption of the internal elastic lamina was unusual in treated grafts but frequent in control grafts. In the adventitia of the control and treated grafts, macrophages, monocytes, and T lymphocytes predominated.

The expression of PDGF-B chain, PDGF-α receptors, TGF-β1, and LTBP was similar in both controls and angiopeptin-treated syngeneic grafts. Only in the case of TGF-β1 was there a nonsignificant, slight reduction in the staining intensity of intima and media of angiopeptin-treated syngeneic grafts.

Discussion

The modulating effect of angiopeptin on accelerated transplant arteriosclerosis was studied in allogeneic and syngeneic aortic transplants in the rat. Furthermore, the expression of various inflammatory and noninflammatory cells and their mediators were investigated. We found that angiopeptin partially inhibited intimal proliferation in the syngeneic grafts but not in the corresponding allogeneic model. Secondly, immunohistochemical stainings of selected inflammatory and noninflammatory cells and their mediators remained nearly unaltered after treatment with angiopeptin in both models.

In the present study, a continuous administration of angiopeptin at a dose of 100 μg/kg per day was selected. The rationale behind this was based upon findings of previous investigations. Continuously administered doses ranging between 20 and 100 μg/kg per day have proven to be effective in inhibiting vascular myointimal proliferation, either following endothelial injury [17] or in the development of transplant atherosclerosis [10, 12, 22]. However, doses below 100 μg/kg per day did not inhibit the incorporation of thymidine at the site of carotid artery injury [17]. In addition, we tested another mode of angiopeptin administration. Angiopeptin was added to the preservation solution, thus allowing angiopeptin to affect grafts immediately after their excision and also during the ischemic period. This was tested in half of the grafts. However, this procedure had no superior effect on intimal proliferation in comparison to rats receiving angiopeptin by mini-osmotic pumps alone. Therefore, all angiopeptin-treated rats were considered as one group.

In our study, angiopeptin did not inhibit intimal thickening in the allogeneic grafts. This lack of effect could be explained by the fact that angiopeptin may have no immunomodulatory effect on immune cells as

![Fig.2 A, B Photomicrographic sections of syngeneic grafts ischemic for 4 h seen 8 weeks after transplantation, van Gieson's stain, ×250: A control graft with pronounced intimal thickness; B reduced intimal thickness after angiopeptin treatment (i intima, m media, a adventitia, iel internal elastic lamina) Occasionally, T lymphocytes, monocytes, and macrophages occurred in the media of allogeneic grafts. Monocytes, macrophages, and T lymphocytes predominated in the adventitia of control and treated allogeneic grafts.

Syngeneic grafts

In the intimal thickening of the control and angiopeptin-treated syngeneic grafts, an infiltration of α-actin containing SMCs, monocytes, and macrophages was seen. In some angiopeptin-treated grafts with less marked intimal thickening, fewer SMCs were present, but the staining intensity of α-actin was similar to that in those control rats with increased intimal thickening. Expression
Table 2  Immunohistochemical stainings of aortic grafts

| Antibodies                  | Syngeneic Control n = 15 | Angiopeptin n = 16 | Allogeneic Control n = 10 | Angiopeptin n = 16 |
|-----------------------------|--------------------------|-------------------|---------------------------|-------------------|
| **A. Intima**               |                          |                   |                           |                   |
| Macrophages                 |                          |                   |                           |                   |
| • ED2                       | 0.13 ± 0.13              | 0.00 ± 0.00       | 0.08 ± 0.08               | 0.14 ± 0.09       |
| Monocytes, macrophages      | 0.38 ± 0.24              | 0.38 ± 0.08       | 1.25 ± 0.18               | 2.00 ± 0.34       |
| • ED1                       | 0.25 ± 0.25              | 0.25 ± 0.13       | 0.33 ± 0.21               | 0.67 ± 0.21       |
| CD4⁺ T lymphocytes          | 0.25 ± 0.25              | 0.62 ± 0.62       | 0.42 ± 0.20               | 0.93 ± 0.20       |
| • W3/25                     | 0.75 ± 0.43              | 0.31 ± 0.09       | 1.75 ± 0.21               | 1.50 ± 0.50       |
| CD8⁺ T lymphocytes          | 0.75 ± 0.43              | 0.31 ± 0.09       | 1.75 ± 0.21               | 1.50 ± 0.50       |
| • Ox8                       | 0.75 ± 0.43              | 0.31 ± 0.09       | 1.75 ± 0.21               | 1.50 ± 0.50       |
| MHC class II antigen        | 1.75 ± 0.75              | 2.13 ± 0.30       | 2.90 ± 0.10               | 2.20 ± 0.46       |
| • Ox6                       | 1.75 ± 0.75              | 2.13 ± 0.30       | 2.90 ± 0.10               | 2.20 ± 0.46       |
| SMCs                        | 0.62 ± 0.24              | 0.17 ± 0.17       |                           |                   |
| • α-actin                   | 0.00 ± 0.00              | 0.00 ± 0.00       |                           |                   |
| TGF-β₁                      | 0.13 ± 0.13              | 0.28 ± 0.18       |                           |                   |
| • Ab96                      | 0.38 ± 0.18              | 0.30 ± 0.20       |                           |                   |
| TGF-β₂                      | 0.00 ± 0.00              | 0.00 ± 0.00       |                           |                   |
| • Ab95                      | 0.13 ± 0.13              | 0.28 ± 0.18       |                           |                   |
| LTBP                        | 0.13 ± 0.13              | 0.28 ± 0.18       |                           |                   |
| • Ab39                      | 0.38 ± 0.18              | 0.30 ± 0.20       |                           |                   |
| PDGF-B chain                | 0.00 ± 0.00              | 0.13 ± 0.13       |                           |                   |
| • PGF-007                   | 0.00 ± 0.00              | 0.13 ± 0.13       |                           |                   |
| PDGF-α receptors            | 0.00 ± 0.00              | 0.13 ± 0.13       |                           |                   |
| • PDGFR-7                   | 0.00 ± 0.00              | 0.13 ± 0.13       |                           |                   |

Mean ± SEM values of semiquantitative evaluations, scale: 0 - 3

| Antibodies                  | Syngeneic Control n = 15 | Angiopeptin n = 16 | Allogeneic Control n = 10 | Angiopeptin n = 16 |
|-----------------------------|--------------------------|-------------------|---------------------------|-------------------|
| **B. Media**                |                          |                   |                           |                   |
| Macrophages                 | 0.25 ± 0.14              | 0.00 ± 0.00       | 0.08 ± 0.08               | 0.00 ± 0.00       |
| Monocytes, macrophages      | 0.63 ± 0.32              | 0.31 ± 0.09       | 1.08 ± 0.42               | 1.83 ± 0.54       |
| • ED1                       | 0.25 ± 0.25              | 0.25 ± 0.94       |                           |                   |
| CD4⁺ T lymphocytes          | 0.25 ± 0.25              | 0.25 ± 0.94       | 0.83 ± 0.17               | 0.67 ± 0.17       |
| • W3/25                     | 0.38 ± 0.24              | 0.06 ± 0.06       | 0.25 ± 0.11               | 0.93 ± 0.20       |
| CD8⁺ T lymphocytes          | 0.50 ± 0.50              | 0.06 ± 0.06       | 2.30 ± 0.20               | 2.00 ± 0.32       |
| • Ox8                       | 2.38 ± 0.47              | 2.38 ± 0.18       | 0.30 ± 0.12               | 0.67 ± 0.30       |
| MHC class II antigen        | 0.94 ± 0.20              | 0.58 ± 0.12       |                           |                   |
| • Ox6                       | 0.00 ± 0.00              | 0.00 ± 0.00       |                           |                   |
| SMCs                        | 0.56 ± 0.13              | 0.62 ± 0.18       |                           |                   |
| • α-actin                   | 0.56 ± 0.13              | 0.62 ± 0.18       |                           |                   |
| TGF-β₁                      | 0.50 ± 0.19              | 0.25 ± 0.17       |                           |                   |
| • Ab96                      | 0.50 ± 0.19              | 0.25 ± 0.17       |                           |                   |
| TGF-β₂                      | 0.21 ± 0.15              | 0.31 ± 0.09       |                           |                   |
| • Ab95                      | 0.21 ± 0.15              | 0.31 ± 0.09       |                           |                   |
| LTBP                        | 0.00 ± 0.00              | 0.00 ± 0.00       |                           |                   |
| • Ab39                      | 0.00 ± 0.00              | 0.00 ± 0.00       |                           |                   |
| PDGF-B chain                | 0.00 ± 0.00              | 0.00 ± 0.00       |                           |                   |
| • PGF-007                   | 0.00 ± 0.00              | 0.00 ± 0.00       |                           |                   |
| PDGF-α receptors            | 0.00 ± 0.00              | 0.00 ± 0.00       |                           |                   |
| • PDGFR-7                   | 0.00 ± 0.00              | 0.00 ± 0.00       |                           |                   |

Mean ± SEM values of semiquantitative evaluations, scale: 0 - 3
no additional immunosuppressive regimen was used. Thus, angiopeptin could not reverse the intimal thickening caused by the combination of immunological and inflammatory mechanisms on the driving proliferative forces in the allogeneic grafts. In other models of allogeneic transplantation, angiopeptin was reported to be beneficial. Angiopeptin treatment reduced the development of transplant atherosclerosis in coronary arteries in an allogeneic heart transplantation model both in rabbits [12] and in rats [10]. In both of these models, however, the animals were treated with cyclosporin A immunosuppression. In contrast, Mennander et al. found that angiopeptin reduced both the number of SMCs and the intimal thickening without immunosuppression in an allogeneic aortic graft model. Compared with our results this difference may be explained by the different inbred rat strains used [from WF (AGB2-RT1) donors to DA (AGB4-RT1) recipients]. However, in their model, the beneficial effect of angiopeptin did not last longer than 3 months in spite of continuous medication, thus leading to final results comparable to ours [22]. We have observed that the media is thinner in the allogeneic grafts than in the syngeneic grafts. The reason for this, as observed by other investigators as well, is probably migration of SMCs [11, 17, 25] and/or medial necrosis due to cytotoxic effects of cell mediators in the allogeneic immunological reaction [20, 21].

The CVR-like changes in the syngeneic grafts were induced by the ischemia/reperfusion injury in our model. We were able to demonstrate a beneficial effect of angiopeptin in this syngeneic group. Ischemia/reperfusion injury in grafts has been recognized as crucial for graft outcome [5]. The relevance of this type of injury to the long-term survival of the transplant has recently been studied and the results are still controversial [18, 40]. Previously, with our model, however, a positive correlation between the duration of ischemia and intimal thickening was noted in the syngeneic grafts but not in the allogeneic grafts [38]. Based on our earlier results, the syngeneic grafts were exposed to a prolonged ischemia of 4 h. This syngeneic model represents non-immunologically induced transplant arteriosclerosis. Angiopeptin may have its main inhibitory effect on cells other than immune cells, such as SMCs and/or endothelial cells. It has been proposed that endothelial cells secrete factors that inhibit SMC proliferation in a paracrine fashion. In the absence of these factors, the SMCs may respond to chemotactic and mitogenic signals. It has been suggested that angiopeptin is functionally related to this "paracrine inhibitor" [17]. Several mechanisms have been proposed to explain how angiopeptin inhibits accelerated arteriosclerosis following vascular injury. These include inhibition of growth factors such as PDGF, insulin-like growth factor-1, and epidermal growth factor, and inhibition of the proliferation and migration of SMCs [17]. In the same aortic transplant model, it was found that the expression of PDGF and TGF-β increases after transplantation (J. Walfenberger et al., unpublished data). The expression of PDGF and TGF-β was only studied in the syngeneic grafts, since the inhibitory effects of angiopeptin were morphometrically seen only in the syngeneic grafts. We did not observe any differences in the expression of PDGF-B chain, PDGF α-receptors, TGF-β1, TGF-β3, or LTBP in control or angiopeptin-treated syngeneic grafts after 8 weeks. However, one cannot exclude the possibility that the expression of these growth factors increased in an earlier phase of transplant arteriosclerosis.

Angiopeptin interferes with myointimal proliferation is not entirely understood. In the ischemia/reperfusion-induced syngeneic transplant model, intimal thickening is reduced by angiopeptin treatment whereas no inhibition was evident in allografts when no immunosuppression was used. Immunosuppressive treatment may be required in allograft recipients for angiopeptin to have an inhibitory effect on intimal thickening. Angiopeptin may counteract ischemia/reperfusion-induced chronic vascular rejection and, thus, benefit the long-term survival of transplanted organs.

Acknowledgements We appreciate the excellent technical assistance of U. Svensson. We express our thanks to A. F. Williams (Oxford, England) and to L. Claesson (Ludwig Institute for Cancer Research, Uppsala, Sweden) for providing the hybridomas W3/25, OX8, and OX6 and PDGF-R-7 antibody against PDGF α-receptors, respectively. This work was supported by the Swedish Medical Research Council, the National Heart and Lung Foundation, the Maud and Birger Gustafsson Foundation and the Society of Kidney Disease in the County of CUWX.

References

1. Agro A, Padol I, Stanisz AM (1991) Immunomodulatory activities of the somatostatin analogue BIM 23014c: effects on murine lymphocyte proliferation and natural killer activity. Regul Pept 32: 129–132
2. Asotra S, Foegh M, Conte JV, Cai BR, Ramwell PW (1989) Inhibition of H-thymidine incorporation by angiopeptin in the aorta of rabbits after balloon angioplasty. Transplant Proc 21: 3695–3696
3. Bhathena SJ, Recant L (1980) Somatostatin receptors on circulating human blood cells. Horm Metab Res 12: 277–278
4. Bodgen AE, Taylor JE, Moreau JP, Coy DH (1990) Treatment of R-3327 prostate tumours with a somatostatin analogue (somatuline) as adjuvant therapy following surgical castration. Cancer Res 50: 2646–2650
5. Bonventre JV, Weinberg JM (1992) Kidney preservation ex vivo for transplantation. Annu Rev Med 43: 523–553
6. Cathapermal SS, Foegh ML, Rau CS, Ramwell PW (1991) Disposition and tissue distribution of angiopeptin in the rat. Drug Metab Dispos 19: 735–739
7. Conte JV, Foegh ML, Calcagno D, Wallace RB, Ramwell PW (1989) Peptide inhibition of myointimal proliferation following angioplasty in rabbits. Transplant Proc 21: 3686–3688

8. Eriksson A, Rorsman C, Erlund A, Claesson-Welsh L, Heldin CH (1992) Ligand induced homo- and heterodimerization of platelet-derived growth factor α- and β-receptors in intact cells. Growth Factors 5: 1–2

9. Fellström B, Dimény E, Larsson E, Klareskog L, Tufveson G, Rubin K (1989) Importance of PDGF receptor expression in accelerated atherosclerosis-chronic rejection. Transplant Proc 4: 3689–3690

10. Fellström B, Dimény E, Foegh ML, Larsson E, Wanders A, Tufveson G (1991) Accelerated atherosclerosis in heart transplants in the rat simulating chronic vascular rejection: effects of prostaacyclin and angiopeptin. Transplant Proc 23: 525–528

11. Foegh ML (1992) Angiopeptin: a treatment for accelerated myointimal hyperplasia ? J Heart Lung Transplant 11: 28–31

12. Foegh ML, Khirabadi BS, Chambers E, Amanoo S, Ramwell PW (1989) Inhibition of coronary artery transplant arteriosclerosis in rabbits with angiopeptin, an octapeptide. Atherosclerosis 78: 229–236

13. Foegh ML, Khirabadi BS, Chambers E, Ramwell PW (1989) Peptide inhibition of accelerated transplant arteriosclerosis. Transplant Proc 21: 3674–3676

14. Jacobsson J, Wahlberg J, Frödin L, Odland B, Tufveson G (1989) Organ flush out solutions and cold storage preservation solutions: effect on organ cooling and post ischemic erythrocyte trapping in kidney grafts. Scand J Urol Nephrol 32: 219–222

15. Juhlin C, Holmdahl R, Johansson H, Rastad J, Åkerström G, Klareskog L (1987) Monoclonal antibodies with exclusive reactivity against parathyroid cells and tubule cells of the kidney. Proc Natl Acad Sci USA 84: 2900–2907

16. Kendall TJ, Wilson JE, Radio SJ, Kandolf R, Guzitza JM, Winters GL, Costanzo-Nordin MR, Malcom GT, Thiesen SL, Miller LW, McManus BM (1992) Cytomegalovirus and other herpes viruses: do they have a role in the development of accelerated coronary arterial disease in human heart allografts? J Heart Lung Transplant 11: 14–20

17. Lundergan C, Foegh ML, Vargas R, Eufemio M, Bormes GW, Kow PA, Ramwell PW (1989) Inhibition of myointimal proliferation of the rat carotid artery by peptides, angiopeptin and BIM2304. Atherosclerosis 80: 49–55

18. Masetti P, DiSesa VJ, Schoen FJ, Sun SC, Byrne JG, Appleyard RF, Laurence R, Cohn LH (1991) Ischemic injury before heart transplantation does not cause coronary arteriopathy in experimental isograft. J Heart Lung Transplant 10: 597–599

19. McMaster R, Williams AF (1979) Identification of ta glycoprotein in the rat thymus and purification from rat spleen. Eur J Immunol 9: 426–433

20. Menander A, Hiisala S, Halttunen J, Ylmaz S, Paavonen T, Häyry P (1991) Chronic rejection in rat aortic allografts. An experimental model for transplant arteriosclerosis. Arterioscler Thromb 11: 671–680

21. Menander A, Paavonen T, Häyry P (1993) Intimal thickening and medial necrosis in allograft arteriosclerosis (chronic rejection) are independently regulated. Arterioscler Thromb 13: 1019–1025

22. Menander A, Rääsinen A, Paavonen T, Häyry P (1993) Chronic rejection in the rat aortic allograft. V. Mechanism of the angiopeptin (BIM23014C) effect on the generation of allograft arteriosclerosis. Transplantation 55: 124–128

23. Olofsson S, Miyazono K, Kanzaki T, Colosetti P, Engström U, Heldin CH (1992) Transforming growth factor-β1, -β2, -β3 secreted by a human glioblastoma cell line. J Biol Chem 267: 19482–19488

24. Parmar H, Charlton CD, PHilies RH, Edwards L, Bejot JL, Thomas F, Lightman SL (1992) Therapeutic response to somatostatin analogue, BIM23014, in metastatic prostatic cancer. Clin Exp Metastasis 10: 3–11

25. Paul LC, Fellström B (1992) Chronic vascular rejection of the heart and the kidney – have rational treatment options emerged? Transplantation 53: 1169–1179

26. Payan DG, Hess CA, Goetzl EJ (1984) Inhibition by somatostatin of the proliferation of T-lymphocytes and molt-4 of human small cell lung carcinoma (NCI-H69) growth by a somatostatin analogue. Biochem Biophys Res Commun 153: 81–86

27. Payan DG, Hess CA, Goetzl EJ (1984) Inhibition by somatostatin of the proliferation of T-lymphocytes and molt-4 of human small cell lung carcinoma (NCI-H69) growth by a somatostatin analogue. Biochem Biophys Res Commun 153: 81–86

28. Parmar H, Charlton CD, PHilies RH, Edwards L, Bejot JL, Thomas F, Lightman SL (1992) Therapeutic response to somatostatin analogue, BIM23014, in metastatic prostatic cancer. Clin Exp Metastasis 10: 3–11

29. Russell R (1993) The pathogenesis of atherosclerosis: a perspective for 1990s. Nature 362: 801–809

30. Sakuda H, Nakashima Y, Kuriyama S, Sueishi K (1992) Media continued by smooth muscle cells cultured in a variety of hypoxic environments stimulates in vitro angiogenesis. A relationship to transforming growth factor-β1. Am J Pathol 141: 1507–1516

31. Scicchitano R, Stanisz AM, Payan DG, Kiyono H, McGee JR, Bienstock J (1987) Expression of substance P and somatostatin receptors on a T helper cell line. Adv Exp Med Biol 216A: 185–190

32. Shiraishi T, Morimoto S, Ikoh K, Sato H, Sugihara K, Onishi T, Ogihara T (1989) Radioimmunoassay of human platelet-derived growth factor using monoclonal antibody towards a synthetic 73–79 fragment of its B-chain. Clin Chim Acta 184: 65–74

33. Stiko-Rahn A, Huiðgárd-Nilsson A, Regnstrom J, Hamsten A, Nilsson J (1992) Oxidised and native LDL enhance production of PDGF-AA and the surface expression of PDGF receptors in cultured human arterial smooth muscle cells. Arterioscler Thromb 12: 1009–1109

34. Taylor JE, Rodgers FE, Moreau JP, Coy DH (1988) In vitro and in vivo inhibition of human small cell lung carcinoma (NCI-H69) growth by a somatostatin analogue. Biochem Biophys Res Commun 153: 81–86

35. Taylor JE, Moreau JP, Baptiste L, Moody TW (1991) Octapeptide analogues of somatostatin inhibit the clonal growth and vasoactive intestinal peptide-stimulated cyclic AMP formation in human small cell lung cancer cells. Peptides 12: 839–843

36. Vargas R, Bormes GW, Wroblewska B, Foegh ML, Kot PA, Ramwell PW (1989) Angiopeptin inhibits thymidine incorporation in rat cardiac artery in vivo. Transplant Proc 21: 3702–3704

37. Waltenberger J, Wanders A, Fellström B, Miyazono K, Heldin CH, Funa K (1993) Induction of transforming growth factor-β during cardiac allograft rejection. J Immunol 151: 1147–1157

38. Wanders A, Akyürek ML, Waltenberger J, Staffberg C, Larsson E, Zhiping R, Funa K, Fellström B (1993) The impact of ischemia time on chronic vascular rejection in the rat – effects of angiopeptin. Transplant Proc 21: 2098-2099

39. Williams AF (1977) Analysis of cell surfaces by xenogeneic myelo-hybrid antibodies: differentiation antigens of rat lymphocytes. Cell 12: 663–673

40. Yilmaz S, Paavonen T, Häyry P (1992) Chronic rejection of rat renal allografts. Transplantation 53: 823–827